Glimepiride tablets USP, are formulated as tablets of: Glimepiride tablets USP, 1 mg are peach, oval, flat beveled edged, uncoated tablets debossed “RDY” on one side and “320” separating “3” and “20” with bisect line scoring on the other side. Glimepiride: Package Insert and Label Information (Page 3 of 3). Use Trial Bulletin to search for clinical trials involving this product: Glimepiride; DrugInserts.com provides trustworthy package insert and label information about marketed drugs as submitted by manufacturers to the US Food and Drug Administration. Package information is not reviewed or updated separately by DrugInserts.com. AMARYL® (glimepiride tablets) 1, 2, and 4 mg. DESCRIPTION. AMARYL ® (glimepiride tablets) is an oral blood-glucose-lowering drug of the sulfonylurea Glimepiride. Glimepiride is a potent medium- to long-acting sulfonylurea (EMA glimepiride opinion following referral, 1998; eMC glimepiride product information, 2012; FDA glimepiride label, 2012). after initiating therapy and increase monitoring in clinical situations where volume contraction is expected [see Use in Specific Populations (8.5)] Glimepiride tablets are contraindicated in patients with a history of a hypersensitivity reaction to: Glimepiride or any of the product’s ingredients [see Warnings and Precautions (5.2) ]. Sulfonamide derivatives: Patients who have developed an allergic reaction to sulfonamide derivatives may develop an allergic reaction to glimepiride. Glimepiride with NDC 16729-002 is a a human prescription drug product labeled by Accord Healthcare Inc. The generic name of Glimepiride is glimepiride. Glimepiride with NDC 43547-396 is a a human prescription drug product labeled by Solco Healthcare U.s., Llc. The generic name of Glimepiride is glimepiride. Concomitant administration of propranolol and glimepiride significantly increased glimepiride C max, AUC, and T 1/2 by 23%, 22%, and 15%, respectively, and decreased glimepiride CL/f by 18%. The recovery of M1 and M2 from urine was not changed. Hypoglycemia. In a randomized, double-blind, placebo-controlled monotherapy trial of 14 weeks duration, patients already on sulfonylurea therapy underwent a 3-week washout period then were randomized to Glimepiride tablets 1 mg, 4 mg, 8 mg or placebo.